Part of the USC/CHLA Cell Therapy Program Seminar Series
James (Jay) Bradner, M.D.
President of the Novartis Institutes for BioMedical Research (NIBR)
Learn more about:
*The innovation of first CART cell therapy, and the outlook for stem-progenitor cell therapy in hematology.
* The design principles for AAV gene therapy, and learnings from Spinal Muscular Atrophy
* Biological engineering strategies to overcome challenges with next-generation Cell & Gene Therapy